Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07418827

Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

Haemophilia is a rare genetic disorder which, in its severe form and in the absence of treatment, can be life-threatening. Since the 1960s and the introduction of coagulation factor concentrates, the life expectancy of people with haemophilia has increased rapidly. Today, for most affected individuals, the disease is experienced as a chronic condition.

The transition process enabling adolescents and young adults (AYA) with a chronic disease to move into adult life can be complex, as they must face all the changes experienced by AYA in general, combined with issues related to their chronic condition and its management.

A successful transition involves a transfer of responsibility from parents to AYA regarding the management of their health condition, as well as the acquisition by AYA of knowledge, skills and autonomy. A difficult transition may lead to decreased adherence to follow-up or treatment, deterioration of overall health status and/or quality of life, or difficulties in entering adult life.

In this context, the national cross-sectional study TRANSHEMO was initiated in 2017. Its objective was to compare adherence to healthcare management between two groups of AYA with severe haemophilia (adolescents [for whom the transition is ongoing] versus young adults [for whom the transition may have been completed]), and to identify the determinants of this adherence. The results showed that young adults had a lower adherence rate than adolescents (82.2% vs. 61.2%, p<0.001). Among the determinants studied, being a young adult, having repeated at least one school year, and presenting psychological and emotional difficulties were factors that had a negative effect on adherence to healthcare management. However, the cross-sectional nature of the study represents a limitation that restricts causal inference. Complementing this project with a longitudinal study would address this limitation.

The results obtained from this new study (TRANSHEMO 2) may contribute to the literature by providing insights into both the determinants of sustained adherence to healthcare management among adolescents with severe haemophilia who become young adults, and the associations between these determinants.

The longitudinal design of the project will allow the establishment of a higher level of causal inference between the maintenance of adherence during the transition to adult life and its determinants, which represents a major epidemiological strength. Moreover, results addressing the issue of transition in the context of chronic diseases and derived from longitudinal studies remain scarce, making the findings of this project particularly original. Finally, haemophilia, a relatively frequent condition among rare diseases, could represent an interesting model for understanding the impact of transition in this type of pathology.

Study hypothesis The extent of the reduction in adherence to healthcare during the transition process, and/or the determinants of the maintenance of adherence identified in the longitudinal TRANSHEMO 2 project, may differ from those highlighted in the original cross-sectional TRANSHEMO project.

Specific aims

Main objective:

To compare the rate of adherence to healthcare among adolescents who participated in the TRANSHEMO project, using data collected during the original TRANSHEMO study when they were adolescents (before transition) and data to be collected as part of the TRANSHEMO 2 study when they have become young adults (after transition).

Secondary objective:

To identify the determinants of the maintenance of this adherence and the associations between these determinants, within the framework of a longitudinal study.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

20 year–29 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU La Reunion, Saint-Denis, La Réunion, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Young adults who participated in the TRANSHEMO project during adolescence and who are currently aged 20-29 years;
  • Young adults with severe haemophilia (haemophilia A or B);
  • Young adults registered in the FranceCoag registry;
  • Young adults who have received the participant information sheet for the TRANSHEMO 2 project;
  • Young adults who did not object to participation in the present study.

Exclusion criteria

  • patients with comprehension difficulties;
  • patients who are unable to read and/or write;
  • patients who express opposition to participation in this study.

Treatment and study plan

questionnaires

Other

Participants will have questionnaires

Primary outcomes

  1. Number of follow-up visits over the last 2 years (FranceCoag registry)

    Time frame: 1 day

    Quantitative variable. Dichotomized in agreement and not in agreement with the recommended number

  2. Rate of Physician-reported adherence to clinical follow-up

    Time frame: 1 day

    Ordinal variable in 5 modalities (Very high/High/Average/Low/Very low). Dichotomized in very high and high to very low.

  3. Rate of Patient-reported adherence to clinical follow-up

    Time frame: 1 day

    Ordinal variable in 2 modalities : visiting Haemophilia Treatment Centre (HTC) at least once a year and Not visiting HTC every year.

  4. If under prophylaxis, number of prophylactic injections over the last 3 months (FranceCoag registry)

    Time frame: 1 day

    Quantitative variable. Dichotomized in agreement and not in agreement with the recommended number.

  5. If under prophylaxis, rate of physician-reported adherence to prophylaxis

    Time frame: 1 day

    Ordinal variable in 5 modalities (Very high/High/Average/Low/Very low). Dichotomized in very high and high to very low.

  6. Rate of Patient-reported adherence to treatment

    Time frame: 1 day

    Nominal variable.

    If under prophylaxis:

    • Dichotomized in having no difficulties in adherence to prophylaxis or having difficulties but missing treatment less than once a week and having difficulties and missing treatment once a week or more

    If under on-demand treatment:

    • Dichotomized in having no difficulties in recognizing early signs of haemorrhage and having difficulties inrecognizing early signs of haemorrhage
  7. Physician-reported number of haemorrhagic events over the last two years

    Time frame: 1 day

    Quantitative variable. Dichotomized in none and at least one

  8. Rate of composite endpoint

    Time frame: 1 day

    A composite quantitative endpoint was created by adding the criteria described above (seven for people under prophylaxis, five for people under ondemandtreatment). Adherent peoplewere defined as those having 4 to 7 points if under prophylaxis, and as those having 3 to 5 points if underon-demand treatment. Dichotomized in adherent and non adherent

Secondary outcomes

  1. Quality of life analysis

    Time frame: 1 day

    Generic quality of life (QoL) measured by Short form 12 Health Survey (SF-12). Two subscores: Physical component score (PCS) for physical health-related quality of life (HRQoL), mental component score (MCS) for mental HRQoL. Scores range from 0 to 100 with higher scores indicating better HRQoL.

  2. Coping strategies analysis

    Time frame: 1 day

    Coping strategies measured by Brief Coping Orientation to Problems Experienced Scale (Brief COPE). 28-item questionnaire evaluating 14 coping strategies, which are grouped into four main strategies: Social support, problem solving, avoidance, and positive thinking. Scores ranged from 0 to 100. Higher scores indicate a more frequent use of the assessed coping strategy

  3. Autonomy analysis

    Time frame: 1 day

    Autonomy measured by autonomy questionnaire Noom. 15-item questionnaire classified into three dimensions: Attitudinal autonomy, Functional autonomy, Emotional autonomy. Scores range from 5 to 25 with higher scores indicating higher level of autonomy

  4. Time perspective analysis

    Time frame: 1 day

    Time perspective measured by Zimbardo Time Perspective Inventory (ZTPI). Two subscales "Negative past" (nine items) and "Future" (12 items) were retained from the original 56-item questionnaire, measuring tendency to focus on different aspects of the past and future. Score range from 1 to 5. Higher scores indicate stronger projection in the assessed time perspective .

  5. Family functioning analysis

    Time frame: 1 day

    Family functioning measured by Family Assessment Device (FAD). 6-item questionnaire. Scores range from 1 to 4 with lower score indicating better general family functioning.

  6. Rate of academic difficulty

    Time frame: 1 day

    Nominal variable with two modalities : at least one grade repetition at school and none

  7. Rate of type of healthcare transition in the HTC

    Time frame: 1 day

    Nominal variable with two modalities : same hospital and service for adolescents and adults and same hospital, two different services (paediatric/adult)

  8. Rate of paediatrician in the medical team of the HTC

    Time frame: 1 day

    Nominal variable with two modalities : yes and no

  9. Rate of setup of therapeutic education activities for transition in the HTC

    Time frame: 1 day

    Nominal variable with two modalities : yes and no

Study contacts

Contact information is provided by the study sponsor or research team.

Noémie Resseguier, MD

CONTACT

[email protected]

0033491324272

Sponsors and collaborators

Lead sponsor

Assistance Publique Hopitaux De Marseille

Other

Registry information

Acronym: TRANSHEMO2

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Feb 18, 2026
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.